NLRP4 and familial pancreatic carcinoma: Furthermore, an Annexin-V/7-AAD experiment showed that there was a significant increase in the rate of apoptosis when NLRP4 knockdown, MitoQ, or CQ was combined with olaparib therapy (Extended Data Fig. 7c, d), suggesting that MitoQ and CQ effectively improved the NLRP4-mediated resistance of pancreatic cancer cells to olaparib.